Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rapport Therapeutics, Inc. - Common Stock (NQ:RAPP)

8.520 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15
Open 8.520
Bid (Size) 6.600 (10)
Ask (Size) 11.07 (1)
Prev. Close 8.520
Today's Range 8.520 - 8.520
52wk Range 6.430 - 29.74
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
nCino Posts Weak Earnings, Joins Tesla And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Why Sportsman's Warehouse Shares Are Trading Higher By Around 39%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Performance

YTD
-53.7%
-53.7%
1 Month
-14.7%
-14.7%
3 Month
-53.7%
-53.7%
6 Month
-53.5%
-53.5%
1 Year
-59.0%
-59.0%

More News

Read More
Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Why Gap Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Via Chartmill
Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics to Participate in Upcoming Investor Conferences
From Rapport Therapeutics, Inc.
Via GlobeNewswire
CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November
From Rapport Therapeutics, Inc.
Via GlobeNewswire
This Rapport Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit
From Rapport Therapeutics, Inc.
Via GlobeNewswire
The 3 Best Healthcare Stocks to Buy in August 2024
Via InvestorPlace
RAPP Stock Earnings: Rapport Therapeutics Misses EPS for Q2 2024
Via InvestorPlace
Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
From Rapport Therapeutics, Inc.
Via GlobeNewswire
3 Under-The-Radar Healthcare Stocks to Buy for Outsized Returns
Via InvestorPlace
Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
From Rapport Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Rapport Therapeutics, Inc. - Common Stock publicly traded?
Yes, Rapport Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Rapport Therapeutics, Inc. - Common Stock trade on?
Rapport Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Rapport Therapeutics, Inc. - Common Stock?
The ticker symbol for Rapport Therapeutics, Inc. - Common Stock is RAPP on the Nasdaq Stock Market
What is the current price of Rapport Therapeutics, Inc. - Common Stock?
The current price of Rapport Therapeutics, Inc. - Common Stock is 8.520
When was Rapport Therapeutics, Inc. - Common Stock last traded?
The last trade of Rapport Therapeutics, Inc. - Common Stock was at 04/03/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.